As of November 8, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Macrogenics, Inc. The largest reported stake is Armistice Capital, LLC's, at 7.88%. 17 filings are on record since July 7, 2025 (Schedule 13G/A, August 14, 2026).
Sell to companies like Macrogenics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 5,006,752 · Sole dispositive: 0 · Shared dispositive: 5,006,752 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Bank Of America Corp · Sole voting: 0 · Shared voting: 2,556,475 · Sole dispositive: 0 · Shared dispositive: 2,556,475 · SCHEDULE 13G/A, 2026-08-03
- · Reporting person: BlackRock, Inc. · Sole voting: 4,447,312 · Shared voting: 0 · Sole dispositive: 4,503,913 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29
- · Reporting person: Millennium Management LLC · Sole voting: 0 · Shared voting: 2,374,296 · Sole dispositive: 0 · Shared dispositive: 2,374,296 · SCHEDULE 13G/A, 2026-07-20
- · Holder: Millennium Management LLC · Percent: 5.4% · SCHEDULE 13G
Macrogenics, Inc. has 17 Schedule 13D or 13G filings on record since 2025-07-07. 2 holders' latest filing reports 5% or more of common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Armistice Capital, LLC | 7.88% | 5,006,752 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 7.1% | 4,503,913 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| Bank Of America Corp | 4% | 2,556,475 | SCHEDULE 13G/A, 2026-08-03 | 2026-06-30 |
| Millennium Management LLC | 3.7% | 2,374,296 | SCHEDULE 13G/A, 2026-07-20 | 2026-06-30 |
| Wasatch Advisors LP | 3.1% | 1,950,287 | SCHEDULE 13G/A, 2025-11-12 | 2025-09-30 |
| Bellevue Group AG | 0% | 0 | SCHEDULE 13G/A, 2026-01-06 | 2025-12-05 |
| Frazier Life Sciences Public Fund, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Macrogenics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Macrogenics, Inc. and the records around it.
Macrogenics, Inc. elsewhere on the record
Companies that share a holder
- Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Jade Biosciences, Inc. (Aug 2026), Celldex Therapeutics, Inc. (May 2026)
- Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026)
- Wasatch Advisors LP also filed stake reports on 72 other companies: Smith Douglas Homes Corp (Oct 2026), Amtech Systems Inc (Oct 2026), BBB Foods Inc (Oct 2026)
Watch Macrogenics, Inc.
Get an email when Macrogenics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Macrogenics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Macrogenics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Macrogenics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 0 | 5,006,752 | 0 | 5,006,752 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Boyd | 0 | 5,006,752 | 0 | 5,006,752 | SCHEDULE 13G/A, 2026-08-14 |
| BlackRock, Inc. | 4,447,312 | 0 | 4,503,913 | 0 | SCHEDULE 13G, 2026-07-29 |
| Bank Of America Corp | 0 | 2,556,475 | 0 | 2,556,475 | SCHEDULE 13G/A, 2026-08-03 |
| Millennium Management LLC | 0 | 2,374,296 | 0 | 2,374,296 | SCHEDULE 13G/A, 2026-07-20 |
| Millennium Group Management LLC | 0 | 2,374,296 | 0 | 2,374,296 | SCHEDULE 13G/A, 2026-07-20 |
| Israel A. Englander | 0 | 2,374,296 | 0 | 2,374,296 | SCHEDULE 13G/A, 2026-07-20 |
The latest filing identifies Macrogenics, Inc. by CUSIP 556099109 and gives its principal executive office as 9704 Medical Center Drive, Rockville, MD 20850 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-07 | Bellevue Group AG | 15.7% | SCHEDULE 13G |
| 2025-07-17 | BlackRock, Inc. | 2.9% | SCHEDULE 13G/A |
| 2025-08-14 | Armistice Capital, LLC | 9.45% | SCHEDULE 13G/A |
| 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 2.5% | SCHEDULE 13G/A |
| 2025-11-12 | Wasatch Advisors LP | 3.1% | SCHEDULE 13G/A |
| 2026-01-06 | Bellevue Group AG | 0% | SCHEDULE 13G/A |
| 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 0% | SCHEDULE 13G/A |
| 2026-02-17 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-14 | Bank Of America Corp | 5.1% | SCHEDULE 13G |
| 2026-05-14 | Millennium Management LLC | 4.8% | SCHEDULE 13G |
| 2026-05-15 | Armistice Capital, LLC | 9.46% | SCHEDULE 13G/A |
| 2026-06-05 | Millennium Management LLC | 5.4% | SCHEDULE 13G |
| 2026-07-20 | Millennium Management LLC | 3.7% | SCHEDULE 13G/A |
| 2026-07-29 | BlackRock, Inc. | 7.1% | SCHEDULE 13G |
| 2026-08-03 | Bank Of America Corp | 4% | SCHEDULE 13G/A |
| 2026-08-14 | Armistice Capital, LLC | 7.88% | SCHEDULE 13G/A |
Questions about who owns Macrogenics, Inc.
Who owns Macrogenics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Macrogenics, Inc.: Armistice Capital, LLC (7.88%, Schedule 13G/A, filed 2026-08-14) and BlackRock, Inc. (7.1%, Schedule 13G, filed 2026-07-29).
Who are the largest shareholders of Macrogenics, Inc.?
By the share each holder's latest filing reports, the largest holders of Macrogenics, Inc. on this page are Armistice Capital, LLC (7.88%) and BlackRock, Inc. (7.1%).
When did Armistice Capital, LLC buy into Macrogenics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Armistice Capital, LLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 9.45%; its latest, Schedule 13G/A filed 2026-08-14, reports 7.88%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Macrogenics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 3, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| July 8, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Macrogenics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.